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Background. Patient frailty amongst patients with non-
valvular atrial fibrillation (NVAF) is associated with
adverse health outcomes and increased risk ofmortal-
ity. Additional evidence is needed to evaluate effective
and safe NVAF treatment in this patient population.
Objectives. This subgroup analysis of the ARISTO-
PHANES study compared the risk of stroke/systemic
embolism (S/SE) and major bleeding (MB) amongst
frail NVAF patients prescribed nonvitamin K antago-
nist oral anticoagulants (NOACs) or warfarin.
Methods. This comparative retrospective observa-
tional study of frail, older NVAF patients who
initiated apixaban, dabigatran, rivaroxaban or
warfarin from 01JAN2013-30SEP2015 was con-
ducted using Medicare and 3 US commercial
claims databases. To compare each drug, 6
propensity score-matched (PSM) cohorts were cre-
ated. Patient cohorts were pooled from 4 databases
after PSM. Cox models were used to estimate
hazard ratios (HR) of S/SE and MB.
Results. Amongst NVAF patients, 34% (N = 150 487)
met frailty criteria. Apixaban and rivaroxaban were
associated with a lower risk of S/SE VS warfarin
(apixaban: HR: 0.61, 95% CI: 0.55–0.69; rivaroxa-
ban: HR: 0.79, 95% CI: 0.72–0.87). For MB, apixa-
ban (HR: 0.62, 95% CI: 0.57–0.66) and dabigatran
(HR: 0.79, 95% CI: 0.70–0.89) were associated with a
lower risk and rivaroxaban (HR: 1.14, 95% CI: 1.08–
1.21) was associated with a higher risk VS warfarin.
Conclusion. Amongst this cohort of frail NVAF
patients, NOACs were associated with varying
rates of stroke/SE and MB compared with war-
farin. Due to the lack of real-world data regarding
OAC treatment in frail patients, these results may
inform clinical practice in the treatment of this
patient population.
Keywords: anticoagulation treatment, atrial fibrilla-
tion, cardiology, stroke, warfarin.
Abbreviations: AF, atrial fibrillation; ARISTOPHANES,
Anticoagulants for Reduction In STroke: Observa-
tional Pooled analysis on Health outcomes ANd
Experience of patientS; CHA2DS2-VASc, Conges-
tive heart failure, Hypertension, Age, Diabetes, and
Stroke—Vascular disease, Age, Sex category; HAS-
BLED, Hypertension, Abnormal liver function,
Stroke, Bleeding, Labile international normalized
ratio (unstable/high), Elderly, Drugs or alcohol;
MB, major bleeding; NOAC, non-VKA oral antico-
agulant; NVAF, nonvalvular atrial fibrillation; OAC,
oral anticoagulant; PSM, propensity score match-
ing; S/SE, stroke/systemic embolism; VKA, vita-
min K antagonist.
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Introduction
Frailty is a clinical state characterized by loss of
biological reserves, failure of homoeostatic mecha-
nisms and increased vulnerability to negative
health-related outcomes [1, 2]. Frailty prevalence
increases steadily with age, from ~4% at 65–
69 years to nearly 26% at ≥85 years [3]. Atrial
fibrillation (AF) is the most common arrhythmia
amongst older patients and is associated with high
frailty risk [4, 5]. Moreover, the odds of a frail
classification are 4 times higher for nonvalvular AF
(NVAF) patients VS non-NVAF patients [6].
Since AF is an independent risk factor for stroke,
oral anticoagulants (OACs)—including nonvitamin
K antagonists (VKAs) and non-VKA OACs (NOACs)
—are recommended for stroke prevention amongst
AF patients [7]. Amongst AF patients, in addition to
older age, frailty is associated with increased
stroke incidence, mortality, symptom severity and
length of hospital stay [1, 8-10]. The European
Society of Cardiology guidelines for AF manage-
ment specifies that frail and older patients are
more likely to benefit from OAC than younger
patients, and all available evidences show NOACs
are noninferior to VKA treatment for cardiovascu-
lar risk [11]. However, despite high AF prevalence
amongst frail older patients, a few receive OACs
compared with nonfrail patients [12, 13].
Various frailty measures have been developed, and
whilst there is no operational consensus on defin-
ing frailty amongst older patients, the frailty phe-
notype proposed by Fried et al. has gained
widespread acceptance [14]. It measures frailty by
≥3 of the following criteria: unintentional weight
loss (10 lbs in the past year), self-reported exhaus-
tion, weakness (grip strength), slow walking speed
and low physical activity [14]. Based on the Fried
phenotype, Segal et al. developed a claims-based
frailty indicator to identify frail individuals using
only administrative data [15].
Given the increased risk of both stroke and bleed-
ing in this population, careful evaluation of optimal
treatment strategies is necessary. This analysis of
older (aged ≥ 65 years) frail patients in the ARIS-
TOPHANES (Anticoagulants for Reduction In
STroke: Observational Pooled analysis on Health
outcomes ANd Experience of patientS;
NCT03087487) study aimed to provide comple-
mentary evidence regarding this poorly studied
population by evaluating and comparing the rates
of stroke/systemic embolism (SE), major bleeding
(MB) and all-cause mortality (US Centers for
Medicare & Medicaid Services [CMS] Medicare
population only) amongst NVAF patients newly
prescribed apixaban, dabigatran, rivaroxaban or
warfarin.
Materials and methods
Data sources and patient selection
This study was conducted amongst older frail
NVAF patients newly treated with apixaban, dabi-
gatran, rivaroxaban or warfarin, as a subgroup
analysis of the ARISTOPHANES study [16]. Data
were pooled from the US CMS Medicare database
and 3 US commercial claims databases: the com-
mercial section of the IQVIA PharMetrics PlusTM
Database (’PharMetrics’), the Optum Clinformat-
icsTM Data Mart (’Optum’) and the Humana
Research Database (’Humana’). Collectively, the 4
datasets cover >123 million beneficiaries annually,
accounting for ~38% of the US population. The IBM
Watson MarketScan Commercial Claims and
Encounter database population, which was
assessed in the ARISTOPHANES study, was not
included in this analysis, as all patients were
<65 years of age [16]. The ARISTOPHANES data
description details and pooling process have been
published previously [16, 17]. Patients prescribed
edoxaban were not included in this study given the
insufficient sample size.
Amongst patients included in the ARISTOPHANES
study, older frail patients were further selected for
this analysis, including AF patients with an OAC
pharmacy claim between 1 January 2013 and 30
September 2015 (identification period). The first
NOAC pharmacy claim during the identification
period was designated as the index date for
patients with any NOAC claim; the first warfarin
prescription date was designated as the index date
for those without a NOAC claim [18]. Patient
demographics and clinical characteristics in the
12 months prior to or on the index date were
examined (baseline period).
Patients were excluded from the study if they had
one of the following: (a) an OAC prescription within
12 months before the index date; (b) evidence of
valvular heart disease, venous thromboembolism
(VTE), transient AF (pericarditis, hyperthyroidism,
thyrotoxicosis) or heart valve replacement/trans-
plant during the baseline period; (c) pregnancy
during the study period; (d) hip or knee
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replacement surgery within 6 weeks prior to the
index date; (e) >1 OAC on the index date; (f) ICD-10
code during the study period; and/or (g) follow-up
time of zero days (Fig. 1).
Frailty was defined with an algorithm defined by
Segal et al. (based on the most commonly used
Fried phenotype for frailty), wherein 44 conditions
were considered and evaluated during a 6-month
period [15]. In the final model, 21 variables were
included in the predicted probability of frailty
(range: 0–1). This study measured the 21 variables
(Table S1) during the 12-month baseline period
and used a predicted probability cut-off of 0.20 to
classify individuals as frail, with sensitivity of 35%
and specificity of 91% [15]. Instead of a cut-off of
0.12, which would yield the maximized sensitivity
of 66% and specificity of 73% and a larger sample
size, the more restrictive cut-off of 0.20 was chosen
to assure the accuracy of frail patient identifica-
tion.
Outcome measures
Primary outcomes were stroke/SE, stratified by
ischaemic stroke, haemorrhagic stroke and SE.
The primary safety outcome was MB, stratified by
gastrointestinal (GI) bleeding, intracranial haem-
orrhage and MB in other key sites (Table S2) [19,
20]. The primary outcomes were identified using
inpatient claims with stroke/SE or MB as the
principal (Medicare and Optum) or first-listed
(Humana and PharMetrics) diagnosis. The sec-
ondary outcome was all-cause mortality in the
Medicare population (these data provide reliable
and validated death information from the Social
Security Administration).
Outcomes were measured for the follow-up period,
defined as the time from 1-day postindex date to
the earliest of: 30 days postdiscontinuation date,
switch date, date of death (inpatient and all-cause
death for commercial data and Medicare popula-
tions, respectively), end of continuous health plan
enrolment or study end (30 September 2015).
Statistical analysis
Descriptive analysis was conducted for each treat-
ment cohort. Means and standard deviations were
calculated for continuous variables; numbers and
percentages were reported for categorical variables.
To control for different patient characteristics,
propensity score matching (PSM) was used to
compare NOAC vs warfarin (apixaban vs warfarin,
dabigatran vs warfarin, and rivaroxaban vs war-
farin) and NOAC vs NOAC (apixaban vs dabigatran,
apixaban vs rivaroxaban, and dabigatran vs
rivaroxaban). PSM was conducted in each data-
base using 2 comparative cohorts before pooling
the datasets. Patients were matched 1:1 by propen-
sity scores generated using multivariable logistic
regressions for baseline characteristics, including
demographic and clinical characteristics (see
Table S3 for complete covariate list). Further
details on PSM methodology appear in the litera-
ture [16, 17]. The PSM-adjusted baseline variables
were compared based on standardized differences,
with a threshold of 10% [21].
The incidence rates of stroke/SE, MB and all-cause
death (Medicare only) in the matched population
were calculated using the number of events divided
by total person-years at risk and multiplied by 100,
with Kaplan–Meier curves to illustrate cumulative
rates. Cox proportional hazard models with robust
sandwich estimates were also applied to the PSM
population within the pooled dataset to evaluate
the comparative risks [22]. OAC treatment was
included as the independent variable in the Cox
models because all the matched confounders were
similar after PSM between the 2 comparative arms.
P-values of 0.05 were used as the threshold for
statistical significance.
Subgroup analysis
For the NOAC cohorts, standard-dose (apixaban
5 mg twice a day (BID), dabigatran 150 mg BID,
rivaroxaban 20 mg once a day (QD)) and lower-
dose (apixaban 2.5 mg BID, dabigatran 75 mg
BID, rivaroxaban 15 mg/10 mg QD) patients were
examined separately based on index prescription
dosage (dabigatran 110 mg is not approved in the
United States). Warfarin cohort patients were
matched to NOAC patients with either dosage.
The statistical methods of the main analysis were
used, wherein 1:1 PSM patients in each dataset
were pooled and compared.
Role of the funding source
This study was funded by Pfizer Inc. and Bristol-
Myers Squibb; whilst the authors have financial
relationships with at least 1 of these companies
(see Funding section), neither business entity
influenced the design, conduct or reporting of the
research.
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Fig. 1 Patient Selection Criteria. The study population selected frail NVAF patients who initiated an OAC of interest,
resulting in 6 PSM cohorts ranging from 18 340 to 79 796 matched patients. AF: atrial fibrillation; ICD-9-CM: International
Classification of Diseases, Ninth Revision, Clinical Modification; OAC: oral anticoagulant; VTE: venous thromboembolism.
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IRB approval
Since this study did not involve the collection, use
or transmittal of individually identifiable data, it
was exempt from institutional review board review.
Both the datasets and the security of the offices
where analysis was completed (and where the
datasets are kept) meet the requirements of the
Health Insurance Portability and Accountability
Act of 1996.
Results
After applying the selection criteria, a total of
150 487 frail patients (of the total elderly NVAF
patients) with NVAF were identified, including
35 780 (23.8%) taking apixaban, 9324 (6.2%)
dabigatran, 42 228 (28.1%) rivaroxaban, and
63 155 (42.0%) warfarin patients (Fig. 1). Amongst
the identified frail patients, the mean frailty score
was 0.4 (maximum of 1.0); details on the frailty
indicator appear in Tables S1 and S3. Over 90% of
the patients had CHA2DS2-VASc scores ≥ 4, and
over 80% had HAS-BLED scores ≥ 3, indicating a
high risk of stroke and bleeding. For apixaban,
dabigatran and rivaroxaban patients, 50%, 37%
and 51% had lower dosage regimens, respectively
(Table S3).
The unadjusted incidence rate of stroke/SE—in-
cluding ischaemic stroke, haemorrhagic stroke
and SE—was 2.2 (apixaban), 2.6 (dabigatran), 2.6
(rivaroxaban) and 3.3 (warfarin) per 100 person-
years. The unadjusted incidence rate of MB—
including GI bleeding, ICH and other MB—was
6.1 (apixaban), 7.0 (dabigatran), 10.2 (rivaroxaban)
and 9.4 (warfarin) per 100 person-years, respec-
tively (Table S3).
After 1:1 PSM, a total of 34 594 apixaban-warfarin,
9263 dabigatran–warfarin, 39 898 rivaroxaban–
warfarin, 9170 apixaban–dabigatran, 34 138 apix-
aban–rivaroxaban, and 9235 dabigatran–rivaroxa-
ban PSM pairs were matched. The mean age was
83–84 years for the matched cohorts, and the
mean follow-up time was 6–8 months. All baseline
variables included in the PSM logistic models were
balanced with standardized differences <10%
(Tables S4 and S5).
NOAC–warfarin comparisons
Amongst elderly frail NVAF patients, apixaban
(hazard ratio [HR]: 0.61, 95% CI: 0.55–0.69), and
rivaroxaban use (HR: 0.79, 95% CI: 0.72–0.87)
were associated with a lower risk of stroke/SE
compared with warfarin. Ischaemic stroke was the
most prevalent type of stroke/SE, with a lower risk
in apixaban and rivaroxaban patients compared
with warfarin patients. Apixaban, dabigatran and
rivaroxaban were associated with a lower risk of
haemorrhagic stroke VS warfarin (Fig. 2a).
Regarding MB, apixaban (HR: 0.62, 95% CI: 0.57–
0.66) and dabigatran (HR: 0.79, 95% CI: 0.70–
0.89) were associated with a lower risk compared
with warfarin. Rivaroxaban (HR: 1.14, 95% CI:
1.08–1.21) was associated with a higher risk of MB
compared with warfarin. Likewise, apixaban was
associated with a lower risk, and rivaroxaban was
associated with a higher risk of GI bleeding (the
most prevalent type of MB) compared with war-
farin. All NOACs were associated with a lower risk
of intracranial haemorrhage VS warfarin (Fig. 2a).
NOAC-NOAC comparisons
Apixaban patients had a similar risk of stroke/SE
(HR: 0.83, 95% CI: 0.66-1.06) compared to dabi-
gatran patients and a lower risk of stroke/SE
compared to rivaroxaban (HR: 0.80, 95% CI:
0.70–0.90). Dabigatran patients were associated
with a similar risk of stroke/SE compared to
rivaroxaban (HR: 1.03, 95% CI: 0.83–1.28;
Fig. 2b).
Compared to dabigatran (HR: 0.73, 95% CI: 0.63–
0.85) and rivaroxaban (HR: 0.53, 95% CI: 0.50–
0.57), apixaban was associated with a lower risk of
MB and GI bleeding (HR: 0.61, 95% CI: 0.50–0.76
and HR: 0.46, 95% CI: 0.42–0.50, respectively).
Compared to rivaroxaban, dabigatran was associ-
ated with a lower risk of MB and GI bleeding (HR:
0.71, 95% CI: 0.63–0.80 and HR: 0.77, 95% CI:
0.66–0.89; Fig. 2b).
The Kaplan–Meier curves for cumulative incidence
of stroke/SE and MB in the matched populations
appear in Fig. 3a and b.
All-cause mortality in the CMS population
In the CMS Medicare population, all NOACs were
associated with a lower risk of all-cause mortality
compared with warfarin: apixaban (HR: 0.69, 95%
CI: 0.65-0.73), dabigatran (HR: 0.70, 95% CI: 0.63-
0.78) and rivaroxaban (HR: 0.84, 95% CI: 0.80-
OAC effect/safety: Frail + NVAF / G. Y. H. Lip et al.
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0.89). Apixaban was associated with a lower risk of
all-cause mortality compared with rivaroxaban
(HR: 0.82, 95% CI: 0.78-0.87). There was no
significant difference between apixaban vs dabiga-
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Dose subgroup analysis
Results from the subgroup analysis by dose
showed generally consistent trends with the main
results for standard and low doses (Figure S2).
Discussion
This subgroup analysis of ARISTOPHANES study
showed that amongst frail NVAF patients, apixa-
ban and rivaroxaban use were associated with
lower risk of stroke/SE when compared with
warfarin use. Further, apixaban and dabigatran
were associated with a lower risk of MB, and
rivaroxaban was associated with a higher risk
compared with warfarin. In the elderly frail CMS
Medicare population, all NOACs were associated
with a lower risk of all-cause mortality compared
with warfarin.
Frail NVAF patients are more susceptible to
stroke/SE and MB due to multimorbidity,
polypharmacy and low weight [1]. The frailty index,
a prognostic tool increasingly recognized by physi-
cians, can be created using diagnosis and proce-
dure codes from claims data [23]. There are 2
commonly used frailty indices: the Frailty Pheno-
type (Fried) and Frailty Index (accumulation of
deficits; Mitnitski and Rockwood) [14, 24, 25]. As
mentioned, the Fried model is based on 5 condi-
tions, and the Rockwood Index is based on a
cumulative deficit of items and presented as a
proportion. The Fried model and the Rockwood
Index have been shown to have common charac-
teristics, and both accurately predict adverse out-
comes [26-28]. The Johns Hopkins Claims-based
Frailty Indicator used in this study was developed
by Segal et al. based on the Fried model, which has
been vigorously validated and is the most widely
used frailty instrument [15].
Frailty status is positively associated with
CHA2DS2-VASc and HAS-BLED scores, which sug-
gest that frail patients are likely to receive a greater
benefit from stroke prevention but potential higher
risk of bleeding by taking anticoagulants [29].
However, the data support the use of OACs
amongst frail elderly NVAF patients, as the benefits
outweigh the risks [11]. Compared to nonfrail
patients, frail AF patients were found to have
higher incidence of stroke and death but not MB
[30-32]. However, despite the increased risk of
stroke and death, frailty is amongst the most
common reasons to withhold OAC therapy [8, 33].
Frail AF patients were reported to be significantly
less likely to use warfarin than nonfrail patients
upon hospital admission and discharge across
geriatric medicine, general medicine and cardiol-
ogy services [8]. Several challenges have been
recognized in the administration of warfarin
amongst frail patients, for example required mon-
itoring of time in therapeutic range, reduced
mobility and risk of falls [34]. NOACs, conversely,
are favourable treatment alternatives to warfarin,
due to fixed dosing, steady pharmacokinetics and
no requirement for coagulation monitoring [34].
Moreover, clinical trials have demonstrated NOACs
have noninferior rates of stroke/SE and MB com-
pared with warfarin [35-37], and these trends are
consistent amongst older (≥75 years) NVAF
patients [38-40]. However, no clinical trials com-
paring NOACs VS warfarin have been conducted
specifically amongst frail NVAF patients, who are
also under-represented in clinical trials.
A few real-world studies have examined the com-
parative effectiveness and safety outcomes of
NOACs and warfarin use amongst the frail NVAF
population [41, 42]. Martinez et al. conducted a
retrospective claims study using the US IBM Wat-
son MarketScan data from November 2011
Fig. 2 (a) Propensity Score-Matched Incidence Rates and Hazard Ratios of Stroke/SE and Major Bleeding for NOAC
versus Warfarin. Cox proportional hazard models with robust sandwich estimates were used to evaluate the risk of stroke/
SE and major bleeding. Apixaban and rivaroxaban were associated with a lower risk of stroke/SE compared with warfarin.
Apixaban and dabigatran were associated with a lower risk of major bleeding, and rivaroxaban was associated with a
higher risk of major bleeding compared with warfarin. CI: confidence interval; GI: gastrointestinal; ICH: intracranial
haemorrhage; NOAC: nonvitamin K antagonist oral anticoagulant; SE: systemic embolism. (b) Propensity Score-Matched
Incidence Rates and Hazard Ratios of Stroke/SE and Major Bleeding for NOAC Comparisons. Cox proportional hazard
models with robust sandwich estimates were used to evaluate the risk of stroke/SE and major bleeding and demonstrated
that apixaban has a lower risk of stroke/SE compared with rivaroxaban and both dabigatran and apixaban have a lower
risk of major bleeding compared with rivaroxaban. In addition, apixaban had a lower risk of major bleeding compared with
dabigatran. CI: confidence interval; GI: gastrointestinal; ICH: intracranial haemorrhage; NOAC: nonvitamin K antagonist
oral anticoagulant; SE: systemic embolism.
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through December 2016. This study examined the
risks of stroke/SE and MB between each NOAC
(apixaban n = 1392; dabigatran n = 1,350;
rivaroxaban n = 2635) and warfarin amongst frail
NVAF patients based on the Johns Hopkins
Claims-based Frailty Indicator [41]. With a follow-
up of ≤2 years, compared to warfarin, apixaban
and dabigatran were associated with similar risk of
stroke/SE and MB. Compared with warfarin,
rivaroxaban was associated with a lower risk of
stroke/SE and a similar risk of MB. Another study
of 122 AF patients with self-rated frailty conditions
(a)
(b)
Fig. 3 (a) Cumulative Incidence of Stroke/SE and Major Bleeding in NOAC–Warfarin Propensity Score-Matched Cohorts.
Kaplan–Meier curves were used to compare the cumulative incidence of stroke/SE and major bleeding between NOACs and
warfarin. (b) Cumulative Incidence of Stroke/SE and Major Bleeding in NOAC-NOAC Propensity Score-Matched Cohorts.
Kaplan–Meier curves were used to compare the cumulative incidence of stroke/SE and major bleeding between NOACs.
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showed that NOACs had similar cumulative rates
of bleeding events and stroke/SE VS warfarin [42].
Using pooled claims data and the entire follow-up
period, the present study provided a larger sample
size, hence statistical power, to compare effective-
ness and safety between NOACs and warfarin
amongst frail NVAF patients. Moreover, it con-
ducted dose subgroup analyses. To the best of the
study authors’ knowledge, this report to date
represents the largest cohort of frail patients
treated with NOACs.
Limitations
This study does have several limitations. Given the
nature of retrospective observational studies, no
causal relationships can be examined. In addition,
the datasets engender certain specific limitations.
For example, potential residual confounders such
as over-the-counter aspirin use, serum creatinine/
creatinine clearance and laboratory values are
unavailable and therefore may introduce bias.
Moreover, age is top-coded in several datasets:
the maximum age in PharMetrics is 84 years, and
the maximum age in Optum and Humana is
89 years. Patients older than these thresholds are
set to the maximum age due to privacy concerns;
this may have led to underestimation of age and,
hence, the frailty score. Besides age, complete
mortality information is only available in the CMS
data; for the commercial datasets, only inpatient
deaths can be assessed. With CMS data contribut-
ing to the majority of the study patient population,
potential, but minimal, bias may have been intro-
duced into our analysis. Further, since Interna-
tional Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM), Current Proce-
dural Terminology (CPT) and Healthcare Common
Procedure Coding System (HCPCS) codes were
used to identify the diagnoses and procedures,
some variables in the datasets may lack clinical
accuracy. Additionally, although dose monitoring
for warfarin and a lower dose for NOACs is avail-
able, the lack of information on weight and labo-
ratory data (e.g. time in therapeutic range and
renal function) precluded evaluation of anticoagu-
lation quality or label-adherent dosing. Neverthe-
less, by including patients with potentially poor-
quality OAC treatment, especially for warfarin, this
study may reflect real-world clinical practice [43].
Future studies may investigate the impact of inap-
propriate OAC dosing on clinical outcomes to
further inform clinical practice. Also, the definition
and cut-off for frailty used in this study (developed
by Segal et al.) were reported to provide a sensitiv-
ity of 35% and a specificity of 91%, which whilst
accurate, still has potential for some misclassifi-
cation of frail patients [15]. Reversal agents were
not available at the time of the study; therefore, the
impact of licensed antidotes for patients with life-
threatening bleeding or requiring urgent surgery
was not evaluated. Whilst our study represents a
comprehensive real-world retrospective claims
study amongst older frail NVAF patients comparing
NOACs and warfarin, as well as each NOAC to each
other, more studies are needed to better compre-
hend anticoagulant efficacy and safety in specific
subpopulations.
Conclusion
Amongst elderly frail NVAF patients, apixaban and
rivaroxaban were associated with lower risk of
stroke/SE and NOACs were associated with vary-
ing comparative risks of major bleeding compared
with warfarin. We also found that apixaban was
associated with a lower risk of stroke/SE compared
with rivaroxaban. Apixaban was associated with a
lower risk of MB compared with dabigatran and
rivaroxaban, and dabigatran had a lower risk of
MB compared with rivaroxaban. This is one of the
first real-world studies to compare NOACs in the
elderly frail NVAF population; the results may
facilitate decision-making regarding OACs in frail
patients.
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